TREATMENT WITHOUT MEDICATION

  • Slide Title

    Magvita TMS Therapy System is an easy to use complete system for treating depression

    Button
  • Slide Title

    Magventure's rTMS system is effective and easy to use for psychiatrists who wish to give patients an alternative to antidepressents

    Button
  • Ectron offers effective and simple solutions to ensure treatment quality, consistency and patient comfort.

    Ectron offers effective and simple solutions to ensure treatment quality, consistency and patient comfort.

    Button
How to treat depression without medication..

Depression Treatment with rTMS

Ectron are proud UK suppliers of MagVenture’s depression treatment MagVita TMS Therapy based on rTMS (repetitive transcranial magnetic stimulation) allows psychiatrists to treat the large number of patients not responding to medications or who cannot tolerate side effects such as weight gain and sleep disorder.

MagVita TMS Therapy® is effective and easy to use for psychiatrists who wish to give their patients an alternative to antidepressants. A full TMS depression treatment for patients who have been properly diagnosed by a psychiatrist and found suitable for rTMS depression treatment includes 5 treatment sessions per week during a period of normally 4-6 weeks.

MagVita TMS Therapy® has been CE approved for “Treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode”.

MagVita TMS Therapy® has been FDA cleared and NICE approved for "Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
MagVenture’s depression treatment without medication

The National Institute for Health and Care Excellence (NICE) in the UK has now approved rTMS (Repetitive Transcranial Magnetic Stimulation) as an effective and safe method of treating depression for patients in the UK. Repetitive Transcranial Magnetic Stimulation (rTMS) is a treatment which uses pulsing magnetic fields to activate brain centers associated with mood. The treatment has a number of advantages over traditional medication as it is non-invasive. It does not involve surgery, anesthesia or sedation and it does not have the side effects associated with antidepressants. rTMS has also been shown effective in treating migraine, post-natal depression and pain.

MagVenture’s rTMS system is effective and easy to use for psychiatrists who wish to give patients an alternative to antidepressants.
A full depression treatment for patients who have been properly diagnosed and found suitable for rTMS depression treatment includes an initial session with Motor Threshold (MT) determination, followed by 5 treatment sessions per week during a period of normally 4-6 weeks. MagVenture’s treatment protocol consists of 3.000 brief pulses delivered with a repetition rate of 10 pulses per second in 4-second “trains” with 26-second pauses between “trains”. This 37-minutes procedure is pre-programmed as the standard treatment protocol in MagVenture’s system.

Three steps
MagVenture’s depression system includes the following three steps:
  1. Treatment cap selection and positioning
  2. Motor Threshold determination (MT)
  3. Treatment Session
Motor Threshold Determination has two purposes: to determine the location of the hand area of the motor cortex and to determine stimulation level. Once the motor cortex is found, a line is drawn on the patient's individual cap to show the operator where to place the coil when performing the actual depression treatments.
MT determination should only be performed by medically skilled people. The MT determination is performed on the left hemisphere because the subsequent depression treatments are performed over the left dorsolateral prefrontal cortex (DLPFC). When performing rTMS depression treatment, the stimulation level is defined as 120 % of MT.
121 million people worldwide are affected by depression and the mental disorder is associated with about 850.000 suicides every year. Those are the facts presented by World Health Organization (WHO). Despite advances in pharmacotherapy, depression remains one of the most common and disabling medical illnesses, and WHO has estimated that by the year 2020, major depression will be exceeded only by ischemic heart disease in global disease burden.

A large number of patient suffering from major depression obtain no or inadequate relief from drug therapy and the side effects from antidepressant medication like e.g. sexual dysfunction, weight gain and sleep disorders lead to noncompliance. MagVenture’s system for depression treatment offers an effective therapy free from undesirable side effects. MagVenture’s system is based on rTMS (repetitive transcranial magnetic stimulation) – a method that allows psychiatrists to treat the large number of patients not responding to medication or who cannot tolerate the side effects.
If you would like more information about rTMS for your clinic, please email TMS@ectron.co.uk or call 0117 9413979
Share by: